Brokerages Set LivaNova PLC (NASDAQ:LIVN) Target Price at $74.78
by Teresa Graham · The Cerbat GemLivaNova PLC (NASDAQ:LIVN – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $74.7778.
Several analysts recently weighed in on the company. Barclays upped their price objective on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Stifel Nicolaus set a $80.00 target price on LivaNova in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th.
Check Out Our Latest Report on LivaNova
LivaNova Stock Down 1.9%
LIVN stock opened at $64.53 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $3.53 billion, a PE ratio of -14.47 and a beta of 0.97. LivaNova has a 1-year low of $34.75 and a 1-year high of $71.92. The business’s 50 day simple moving average is $64.75 and its 200 day simple moving average is $61.40.
LivaNova (NASDAQ:LIVN – Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm’s revenue was up 12.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, research analysts anticipate that LivaNova will post 3.66 EPS for the current year.
Hedge Funds Weigh In On LivaNova
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its stake in LivaNova by 168.1% during the third quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock worth $1,421,000 after acquiring an additional 17,007 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in shares of LivaNova during the third quarter worth about $7,687,000. LSV Asset Management grew its holdings in shares of LivaNova by 25.4% during the third quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after purchasing an additional 136,600 shares during the last quarter. Boone Capital Management LLC bought a new stake in shares of LivaNova during the third quarter worth about $8,796,000. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in shares of LivaNova by 8.1% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock worth $18,315,000 after purchasing an additional 26,202 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
LivaNova Company Profile
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.